2023
DOI: 10.3390/cancers15051589
|View full text |Cite
|
Sign up to set email alerts
|

ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast Cancer

Abstract: (1) Purpose: The glycoprotein non-metastatic melanoma B (gpNMB) is a type 1 transmembrane protein that is overexpressed in numerous cancers, including triple-negative breast cancer (TNBC). Its overexpression is associated with lower overall survival of patients with TNBC. Tyrosine kinase inhibitors such as dasatinib can upregulate gpNMB expression, which has the potential to enhance therapeutic targeting with anti-gpNMB antibody drug conjugates such as glembatumumab vedotin (CDX-011). Our primary aim is to qua… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
0
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 30 publications
0
0
0
Order By: Relevance
“…These tracers may have a therapeutic benefit as well. Immunotherapylinked PET/CT also holds promise in optimizing treatment timing [63]. Simultaneously, scanners that are faster, more precise, and easier to use continue to be developed, which will also contribute to improved diagnosis and treatment of head and neck cancer in the future.…”
Section: Recent Advances Conclusion and Future Directionsmentioning
confidence: 99%
“…These tracers may have a therapeutic benefit as well. Immunotherapylinked PET/CT also holds promise in optimizing treatment timing [63]. Simultaneously, scanners that are faster, more precise, and easier to use continue to be developed, which will also contribute to improved diagnosis and treatment of head and neck cancer in the future.…”
Section: Recent Advances Conclusion and Future Directionsmentioning
confidence: 99%